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San Francisco, CaliforniaBACKGROUND & AIMS: In women with inflammatory bowel diseases (IBDs), exposure to immunomodulator or biologic
therapy has not been associated with adverse events during pregnancy or outcomes of
newborns. We investigated whether exposure of patients to these agents during pregnancy
affects serologic responses to vaccines in newborns.METHODS: We collected data from the Pregnancy in IBD and Neonatal Outcomes registry, which records
outcomes of pregnant women with diagnosis of IBD receiving care at multiple centers in the
United States, from 2007 through 2016. Serum samples collected from infants at least 7 months
old were analyzed for titers of antibodies to Haemophilus influenzae B (HiB) or tetanus toxin;
mothers completed a survey of vaccine practices and outcomes from July 2013 through October
2016. Umbilical cord blood samples from 33 infants were assayed for concentration of biologic
agents. Vaccination response was compared between infants born to mothers exposed to bio-
logic therapy (infliximab, adalimumab, certolizumab pegol, golimumab, natalizumab, vedoli-
zumab, or ustekinumab—either as a single agent or in combination with an immunomodulator,
at any time between conception and delivery) and infants born to unexposed mothers.RESULTS: A total of 179 women completed the vaccine survey (26 biologic unexposed, 153 exposed to a
biologic agent). We found no significant difference in proportions of infants with protective
antibody titers against HiB born to exposed mothers (n[ 42, 71%) vs unexposed mothers (n[
8, 50%) (P [ .41). We also found no difference in the proportion of infants with protective
antibody titers to tetanus toxoid born to exposed mothers (80%) vs unexposed mothers (75%)
(P [ .66). The median concentration of infliximab in cord blood did not differ significantly
between infants with vs without protective antibody titers to HiB (P [ .30) or tetanus toxoid
(P [ .93). Mild reactions were observed in 7/40 infants who received rotavirus vaccine and
whose mothers had been exposed to biologic therapies.CONCLUSIONS: Vaccinationof infants againstHiBand tetanus toxin, basedonantibody titersmeasuredwhen infants
were at least 7 months old, does not appear to be affected by in utero exposure to biologic therapy.Keywords: Infliximab; Neonate; Immunization; Rotavirus.aAuthors share co-first authorship.
Abbreviations used in this paper: HiB, Haemophilus influenzae B; PIANO,
Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes; TNF,
tumor necrosis factor.
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https://doi.org/10.1016/j.cgh.2017.08.041Inflammatory bowel diseases (IBDs), such asCrohn’s disease and ulcerative colitis, frequently
affect men and women in their reproductive years.
Because of the progressive, relapsing-remitting course of
disease, many patients with IBD require immunosup-
pressive and biologic therapy to obtain disease control.
Achieving and maintaining adequate disease control is
important to optimize pregnancy outcomes because
active disease is associated with an increase in adverse
pregnancy outcomes.1 The impact of such medications
on fertility, pregnancy, and infant outcomes are ofparamount importance to both the patients and the
treating clinician. There have been multiple retrospective
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anti–tumor necrosis factor (TNF) therapy and adverse
outcomes or congenital malformations in the IBD popula-
tion.2,3 However, some biologics can cross the placenta
and be present in the infant for the first several months
of life.4 There are limited data on the long-term impact of
this exposure on the development of the neonatal im-
mune system. The 2010 case report of the death of an in-
fant born to a mother on biologic therapy who was
administered the Bacillus–Calmette–Guerin vaccine at 3
months remains at the forefront and drives the pursuit
for continued safety in our infants born in the era of bio-
logic therapy.5
Studies have quantified the anti-TNF drug concen-
tration in the mother and infant and have shown that
measurable drug concentration can persist in the infant
for up to 12 months.4,6 This persistence of drug has led
to recommendations for avoiding live vaccines in infants
during the time when they may have detectable con-
centrations of biologic drug. However, no alterations
have been recommended for inactivated vaccines under
the assumption that they are both safe and effective
despite exposure to maternal immunosuppression.
Studies in adults with IBD have shown that individuals
on immunosuppression, particularly combination
immunomodulator-biologic therapy, have significantly
lower rates of response to inactivated vaccines including
pneumococcal and influenza vaccines.7–9 It is unknown
whether an infant exposed to biologic and immuno-
modulator therapy in utero and/or with detectable bio-
logic concentration in the first year of life will mount an
appropriate response to inactivated vaccines.
The Pregnancy in Inflammatory Bowel Disease and
Neonatal Outcomes (PIANO) registry is one of the largest
prospective registries of maternal and childhood out-
comes in IBD. It focuses on both pregnancy outcomes
and early childhood health and development. The aims of
this study were to measure infant response to vaccina-
tions at 1 year of age and determine if maternal immu-
nosuppression exposure affects vaccine response. In
individuals in whom the serum concentration of biologic
drug was available at birth, we aimed to examine if a
higher drug concentration at birth was associated with
an attenuated response to vaccination.
Methods
Study Cohort
The population for this study consisted of women
enrolled in the Crohn’s and Colitis Foundation PIANO
registry, an ongoing prospective multicenter registry
initiated in 2007. This prospective registry approached
women with an established diagnosis of IBD receiving
care at 1 of 30 centers throughout the United States.
Upon obtaining informed consent, women provided
detailed information regarding their demographics andcharacteristics of their IBD, including current and past
treatments. Enrollment could occur at any point during
pregnancy and participating women were followed up
prospectively throughout each trimester of pregnancy,
and at delivery. Children born to these mothers were
followed up every 4 months in the first year of life, and
then annually until the age of 4 years. To date, there have
been 1564 patients enrolled in the PIANO registry. The
survey on vaccine responses was administered to
women who had an infant at least 12 months of age
between July 2013 and October 2016. Among 211 such
women, 179 completed the vaccine survey (85%) and
were included in this analysis. In the United States,
during the first year of life, the Centers for Disease
Control and Prevention recommends hepatitis B vaccines
at birth, age 1 to 2 months, and age 6 months;
diphtheria–tetanus–pertussis, Pneumococcal, inactivated
polio vaccine, and rotavirus at age 2, 4, and 6 months;
Haemophilus influenzae B (HiB) at 2, 4, and 12 months;
and measles, mumps, and rubella at age 12 months.
There were 261 infants who were at least 7 months of
age during this period; 50 mothers agreed to test for
vaccine titers in their infants. Although women could be
enrolled during more than 1 pregnancy in PIANO, there
were no multiple enrollees in this vaccine substudy.
For this study, women and infant pairs were classified
into 2 groups. The biologic-exposed group consisted of
those infants in whom the mother had been exposed to
any biologic therapy (infliximab, adalimumab, certolizu-
mab pegol, golimumab, natalizumab, vedolizumab, or
ustekinumab), either as a single agent or in combination
with an immunomodulator at any time between
conception and delivery. The no-biologic comparator
population consisted of infants whose mothers had been
on mesalamine, antibiotics, steroids, immunomodulator
monotherapy (azathioprine or 6-mercaptopurine), or
received no therapy between conception and delivery.Vaccination Questionnaire and Titer
Measurement
This substudy included all patients with an infant at
least 7 months of age at the time of study initiation.
Women who consented to participate were mailed a
letter to be delivered to their infant’s pediatrician
requesting measurement of vaccination response. A
sample of 2 mL infant blood was obtained to measure
response to tetanus toxoid and HiB vaccination after
completion of primary immunizations at 2, 4, and 6
months of age. Serologic titers were measured at local
laboratories. Vaccination response was considered
adequate (within the immune range for that laboratory)
or inadequate (below the immune range). These 2 vac-
cines were selected because they each represent a
distinct type of antigen; the tetanus toxoid is a
pure protein antigen whereas HiB represents
a protein–polysaccharide conjugate.6 Both vaccines
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studies have reported that between 90% and 100% of
children who completed the primary series achieved
protective antitoxin titers against tetanus toxoid10,11 and
HiB.12–14 Women also were asked specifically if the
rotavirus vaccine was administered, and, if not,
the reason for skipping the vaccine. Information was
obtained about completion of the primary immunization
series and reasons for missed vaccines.
Cord blood and/or infant serum was assayed for
concentrations of infliximab, adalimumab, certolizumab
pegol, vedolizumab, or ustekinumab from a subset of
women enrolled in the study. Maternal, cord, and infant
serum were collected on the day of birth (0.5–2 mL
blood required per sample). If the infant had a detectable
concentration of biologic drug at birth, the site co-
ordinators contacted the mother to obtain additional
infant samples at months 3 and 6, as appropriate.
Maternal and cord blood samples were collected into
tiger-top tubes and from the baby into a gold-top tube.
The specimens then were packaged by hospital phle-
botomy staff or a nurse and shipped ambient to Pro-
metheus Laboratories, Inc (San Diego, CA). Serum
concentrations of all drugs were determined at Prome-
theus Laboratories, Inc, by mobility shift assay as pre-
viously described.15 The assays for infliximab,
adalimumab, and vedolizumab have been validated and
are in routine clinical use.
Statistical Analysis
All statistical analyses were performed at the Data
Management Center at the University of North Carolina
at Chapel Hill. Continuous variables were summarized
using means and SDs and compared using the t test,
whereas categoric variables were expressed in pro-
portions and compared using the chi-square test with
the Fisher exact modification when appropriate. Rates of
adequate vaccination response to tetanus toxoid and HiB
were compared across the biologic-exposed and unex-
posed groups. Univariate logistic regression was per-
formed to quantify the effect of medication exposure on
adequate vaccination response, with a 2-sided P value
less than .05 indicating statistical significance. Analyses
were repeated excluding certolizumab pegol users given
the known minimal transplacental transfer of this agent.
Nonparametric tests were used to compare the median
cord levels of infliximab between vaccine responders
and nonresponders. The study was approved by the
Institutional Review Board at each participating
institution.
Results
The study population included 179 women from the
PIANO registry who completed the vaccination survey.
The mothers’ mean age was 31.6 years and the meandisease duration at the time of pregnancy was 9.5
years (Table 1). Two-thirds (67%) had Crohn’s disease
(n ¼ 120). One third of women each were in their first
(n ¼ 67; 37%) or second pregnancy (n ¼ 55; 31%),
while 24 women (13.4%) were in their fourth or
subsequent pregnancy. Most women had inactive
(77%) or mild disease activity (18%) at the time of
pregnancy. Eleven women (6%) were on no immuno-
suppressive therapy, 15 women (8%) were on immu-
nomodulator therapy, and the remaining women were
on biologics either as monotherapy (116; 65%) or in
combination with an immunomodulator (37; 21%).
There was no statistical difference in the mean age,
type of IBD, smoking status, gravidity, or disease ac-
tivity across the 2 groups (Table 1). Vaccine titers were
available to infants born to 50 women. Characteristics
of mothers with available vaccine titers are shown in
Table 2. Among the 42 biologic-exposed patients, 27
were on infliximab, 7 were on adalimumab, 3 were on
certolizumab, 2 each were on natalizumab and uste-
kinumab, and 1 was on vedolizumab. Eight infants
born to women on immunomodulators alone or no
immunosuppressive therapy formed the comparator
population.
Table 3 describes the percentages of women in
each subgroup whose infants received the scheduled
vaccinations during their first year of life. Most
infants in both groups received hepatitis B,
diphtheria–tetanus–pertussis, inactivated polio, HiB,
pneumococcal, measles-mumps-rubella, and varicella
vaccines. Infants born to women on biologic mono-
therapy or combination therapy (35%) were significantly
less likely to have received the rotavirus vaccine
compared with those on no immunosuppression
(P ¼ .001). Among biologic-exposed infants, the rate of
receiving the rotavirus vaccine was lower in women on
combination therapy (16%) compared with those on
biologic monotherapy (41%; P ¼ .006). A majority of
the women who reported skipping the rotavirus
vaccines for their infants did so on their doctors’ advice
(n ¼ 72), with only 2 and 3 women, respectively,
reporting skipping the dose because of personal prefer-
ence or concern for side effects.
Information on serologic response to the HiB vaccine
and to tetanus toxoid was available for 46 and 49 infants,
respectively (Figure 1). For the HiB vaccine, 71% of
biologic-exposed patients had adequate antibody titers
compared with 50% of unexposed infants (P ¼ .41)
(odds ratio [OR], 2.45; 95% CI, 0.52–11.60). Similarly, for
tetanus toxoid, 80% of infants exposed to biologic ther-
apy showed adequate immune responses compared with
75% of unexposed infants (P ¼ .66; OR, 1.38; 95% CI,
0.23–8.13). There was no difference in response to the
vaccines by type of biologic therapy. The results also
were unchanged when excluding certolizumab pegol,
which has negligible rates of placental transfer (OR for
adequate vaccine response in biologic-exposed compared
with unexposed infants was as follows: HiB: 2.25; 95%
Table 3. Proportion of Infants Receiving at Least 1 Dose of




(n ¼ 26), %
Biologic exposed
(n ¼ 153), % P value
Hepatitis B 81 75 .51
DTAP 85 83 .80
IPV 85 82 .71
HiB 85 83 .80
Pneumococcal 85 83 .80
MMR 81 82 .90
Rotavirus 69 35 .001a
Varicella 81 83 .80
DTAP, diphtheria, tetanus, pertussis; IPV, inactivated polio vaccine; MMR,
measles, mumps, rubella.
aIn the United States, during the first year of life, the Centers for Disease
Control and Prevention recommend hepatitis B vaccines at birth, 1 to 2
months, and 6 months; diphtheria-tetanus-pertussis, pneumococcal, and
inactivated polio vaccine at 2, 4, and 6 months; HiB at 2, 4, and 12 months;
MMR at 12 months; and rotavirus at 2, 4, and 6 months.








Mean age, y (SD) 31.4 (4.6) 33.1 (3.2)
Type of IBD, N (%)
Crohn’s disease 107 (69.9) 13 (50.0)
Ulcerative colitis 43 (28.1) 11 (42.3)
IBDU 3 (2.0) 2 (7.7)
Mean duration of disease, y (SD) 8.9 (6.0) 13.2 (7.6)
Smoking status, N (%)
Never 112 (73.2) 18 (69.2)
Former/current 41 (26.8) 8 (30.8)
Gravidity, N (%)
1 54 (35.3) 13 (50.0)
2 47 (30.7) 8 (30.8)
3 32 (20.9) 1 (3.8)
4 20 (13.1) 4 (15.4)
Disease activity, N (%)
None 117 (77.0) 19 (79.2)
Mild 26 (17.1) 5 (20.8)
Moderate 8 (5.3) 0 (0.0)
Severe 1 (0.7) 0 (0.0)
Medication use, N (%)
Biologics 153 (100.0) 0 (0.0)




IBDU, IBD unspecified; N/A, not applicable.
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Among the 42 women on biologic therapy, 10 were on
combination therapy with an immunomodulator. There
was no difference in the proportion with adequate
serologic response to either HiB (69% vs 78%) or
tetanus (84% vs 67%) between the biologic mono-









Mean age, y (SD) 31.7 (3.4) 30.6 (4.4)
Mean disease duration, y (SD) 10.4 (5.6) 5.3 (2.3)
Type of IBD (%)
Crohn’s disease 30 (71.4) 4 (50.0)
Ulcerative colitis 11 (26.2) 4 (50.0)
IBDU 1 (2.4) 0 (0.0)
Ever smoker (%) 5 (11.9) 2 (25.0)
Disease activity (%)
None 34 (81.0) 5 (62.5)
Mild 8 (19.0) 3 (37.5)
Medication use, N (%)
Biologics 42 (100.0) 0 (0.0)




IBDU, IBD unspecified; N/A, not applicable.Both groups had response rates similar to infants born to
mothers on no immunosuppression.
Serum drug concentrations were available for 29
infants (20 infliximab, 6 adalimumab, and 1 each for
certolizumab, ustekinumab, and vedolizumab) and 33
cord blood samples (23 infliximab, 6 adalimumab, 2
ustekinumab, and 1 each for vedolizumab and certoli-
zumab). For tetanus toxoid, there was no difference
between the rates of response in infants with unde-
tectable (50%), therapeutic (3–10 mcg/mL; 100%), high
(10.1–20 mcg/mL; 83%), and very high (>20 mcg/mL)
biologic concentrations (P ¼ .37). Similarly, there was no
association between response to HiB across the same 4
categories (50%, 83%, 100%, and 59%, respectively;
P ¼ .22). Because infliximab was the most commonly
used biologic, we performed a subgroup analysis of
women on this therapy. There was no association be-
tween infliximab concentration in cord blood and ade-
quacy of immune response to HiB or tetanus vaccines
(Figure 2). The median cord blood infliximab concen-
trations were similar between infants with an adequate
(24.3 mcg/mL; interquartile range, 14.0–42.7 mcg/mL)
or inadequate immune response to HiB (43.0 mcg/mL;
interquartile range, 28.5–53.3) (P ¼ .31). Similarly, for
tetanus toxoid, there was no difference in the median
infant cord level between those with (31.4 mcg/mL) and
without (41.5 mcg/mL) an adequate immune response
(P ¼ .93).
Infants born to 43 of the women on biologics (19
infliximab, 12 certolizumab, 7 adalimumab, 1 infliximab and
certolizumab, and 1 ustekinumab) received the rotavirus
vaccines. Among infants of 40 women for whom these data
were available, 7 (17.5%) reported a reaction to the vaccine.
Of these, 6 infants had a fever (5 infliximab, 1 adalimumab)
and1haddiarrhea (on infliximab). Therewasno correlation
between infant drug concentration at birth and the likeli-
hood of a reaction to the rotavirus vaccine (Table 4).
Figure 1. Proportion of infants with protective titers to HiB
and tetanus vaccine, by maternal biologic use. A total of 46
(38 biologic exposed, 8 unexposed) and 49 (41 biologic
exposed, 8 unexposed) infants had an available vaccine titer
response to HiB and tetanus, respectively.
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The impact of medications used for the management
of maternal IBD on the health and development of infants
historically has not been studied systematically. With
data showing that in utero exposure to some biologics
leads to persistence of drug concentrations for up to a
year, there is a need for robust examination of this effect
on infant immune response. By using data from a
rigorously followed up prospective cohort of pregnant
women with IBD, we show that the rates of adequate
serologic response to HiB and tetanus vaccines wereFigure 2. Association between the cord blood concentration of i
(A) HiB. The median infliximab cord blood levels in infants with a
and 43.0 mcg/mL, respectively (P ¼ .30). (B) Tetanus toxoid. Th
and inadequate serologic response to tetanus were 31.4 and 4similar among infants born to women on biologic ther-
apy compared with those who were not biologic users
during pregnancy. There was also no association
between cord blood or infant serum concentrations of
biologics and adequacy of vaccine titers. In a small subset
of infants exposed to maternal biologic therapy, rotavirus
vaccine was administered without serious adverse
reactions and with mild events occurring at a rate similar
to that expected in the general population, suggesting a
need for further studies in this population.
There is a significant body of literature examining the
effect of immunosuppression on response to vaccination
in patients with IBD, primarily in response to the influ-
enza vaccine.9 Mamula et al9 studied 80 children (51
with IBD) who received a single dose of the inactivated
influenza vaccine. Compared with healthy controls,
nearly all of whom (89%–100%) developed protective
titers to 3 different influenza virus antigens, only 33% to
85% of patients with IBD showed protection for all 3
antigens. The reduced serologic response was more
striking in patients on combination therapy. Some
studies identified similar rates of initial response, but
reduced persistence of the seroprotective titers at 2
years.16 In adult IBD patients, Melmed et al3 showed that
those on combination anti-TNF immunomodulator ther-
apy had lower rates of response to the pneumococcal
polysaccharide vaccine (45% vs 80% with no immuno-
suppression). Dezfoli et al17 showed lower rates of
response to the tetanus vaccine in patients on combi-
nation therapy with anti-TNF and immunomodulator
compared with those on no immunosuppression.
Examination of the adequacy of vaccine response in
infants born to women on biologic therapy attained
additional impetus, with emergence of data suggesting
persistence of detectable biologic concentrations in in-
fants for many months after delivery. A prospective
observational cohort by Julsgaard et al4 showed that
infliximab concentration could persist for up to 12
months and adalimumab for 9 months after birth. In
contrast, certolizumab pegol, by virtue of being anfliximab and the response to HiB or tetanus toxoid vaccines.
dequate and inadequate serologic response to HiB were 24.3
e median infliximab cord blood levels in infants with adequate
1.5 mcg/mL, respectively (P ¼ .93).
Table 4. Characteristics of Infants Born to Mothers on Biologic Therapy Who Received the Rotavirus Vaccine
Biologic therapy Number Proportion with reaction, N (%) Type of reaction Biologic level in infant, mcg/mL
Infliximab 19 6 (32) Fever (n ¼ 5)
Diarrhea (n ¼ 1)
Diarrhea: 72 mcg/mL (at birth; 5 mcg/mL (at 3 mo)
No reactions: 44, 11, 42, 28, 22, and 69 mcg/mL
Adalimumab 7 1 (14) Fever (n ¼ 1) No reaction: 14, 7 mcg/mL
Certolizumab 12 0 (0) - No reaction: 5 mcg/mL
Ustekinumab 1 0 None No reaction: 40 mcg/mL
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bind to the neonatal Fcg receptor responsible for
transplacental transfer and was not found in infant or
cord blood.18 In this context, it is reassuring to note that
in our study, infants exposed to maternal biologic (or
immunomodulator therapy) had similar rates of sero-
logic response to HiB or tetanus vaccines compared with
infants of unexposed women in our cohort. However, the
overall rates of adequate response to HiB and tetanus in
our cohort, 67% and 80%, respectively, were lower than
noted historically. Prior studies reported that between
90% and 100% of children who completed the primary
series achieved protective antitoxin titers against tetanus
toxoid10,11 or HiB.12,13 Two reasons could explain the
lower rates of response observed in our cohort: a
possible immunosuppressive effect of maternal IBD itself
or the impact of in utero exposure to maternal immu-
nosuppressive and biologic use, which our small sample
size prevents us from distinguishing.
Despite the recommendations to avoid live vaccines
in infants born to mothers on biologic therapy, infants
born to 43 women on biologics received the rotavirus
vaccine with just fewer than 1 in 5 developing a minor
reaction. This is comparable with the rates of fever
(42%) or diarrhea (19%) reported in the healthy infants
in the general population in the Vesikari et al19 publi-
cation that included more than 34,000 infants. In addi-
tion, it has been reported that the first dose of rotavirus
vaccine given after 3 months of age in healthy infants
was associated with an increased risk of intussuscep-
tion.20,21 Prior studies of infants with severe immuno-
deficiency have shown severe live vaccine associated
reactions22 and Cheent et al5 described a case of severe,
disseminated Bacillus–Calmette–Guerin infection result-
ing in death after vaccination at 3 months in an infant
exposed to maternal infliximab. In a systematic review,
Croce et al23 described the safety of live vaccines in
21,082 patients on immunosuppressive therapy for
immune-mediated disease (majority of study sample) or
organ transplantation, most of whom received the herpes
zoster vaccine. Local or systemic reactions were infre-
quent, occurring in 1.3% of the cohort. However, none of
the reports described patients receiving the rotavirus
vaccine. Despite our data suggesting a lack of severe side
effects with the rotavirus vaccine in these infants, in the
absence of robust evidence, one should continue to avoid
live vaccines in infants born to mothers on biologictherapy (excluding certolizumab) during the first year of
life or until drug clearance is confirmed. With the
growing availability of tests, one conceivably could test
serum drug concentration in infants, and, if undetectable,
consider live vaccination at that time, if appropriate for
the vaccine, particularly in infants most likely to benefit
from such vaccines.
We acknowledge several limitations to our study.
Although this was a large study of vaccination response in
infants of mothers on immunosuppressive and biologic
medications, the number of children, particularly on no
immunosuppression, was small and thus provided limited
statistical power. However, of note, a few prior studies on
vaccine responses in individuals with IBD had only
modestly larger sample sizes (60–64 patients) and
showed a statistically significant reduction in serologic
response in immunosuppressed individuals. In addition,
inclusion in this study relied on thewillingness of mothers
to subject their healthy, unaffected infants to invasive
blood draws at older than 7 months of age, which was an
understandable practical constraint, limiting sample size.
We assessed the serologic response to only 2 vaccines,
chosen because they provide a window into immune re-
sponses to protein and protein–polysaccharide vaccines.
Drug levels were analyzed at a single time point (birth)
given the smaller number of patients with levels available
at 3 and 6 months. Because the vaccines are administered
at multiple time points, measurement of infant infliximab
levels at each of these doses would be impractical. There
is a need for future studies to examine the sustainability of
response to vaccination in such infants.
In conclusion, despite the growing body of literature
showing that both conventional immunomodulator
therapy with thiopurines (6-mercaptopurine, azathio-
prine), TNFa antagonists, anti-integrin, or
anti-interleukin 12/23 therapies are low risk during
pregnancy and are not associated with congenital
anomalies and pregnancy outcomes, the short- and long-
term impacts on immune response in the infant has yet
to be determined. This study was a large prospective
study that looked at infants exposed to maternal immu-
nomodulator or biologic use and infant vaccine response.
In our infants, maternal immunosuppression use was not
associated with lower rates of response to tetanus or HiB
vaccines compared with unexposed infants of mothers
with IBD, however, overall rates of response were lower
than historically reported. In a limited cohort of exposed
January 2018 Maternal Immunosuppression and Serologic Response to Vaccines in Infants 105infants given the rotavirus vaccine, there was no asso-
ciation with significant adverse reactions.References
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